- Jubilant Biosys Limited has opened a new discovery and preclinical facility in Noida (Delhi NCR), doubling its chemistry capacity for discovery research and scale-up projects.
- The multimillion-dollar site integrates discovery laboratories with pilot plants and supports quantities from hundreds of grams up to 25 kg.
Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has opened a new discovery and preclinical facility in Noida (Delhi NCR), expanding its chemistry capabilities for discovery research and early-phase scale-up. The company operates as a global CRDMO from five sites across India and Europe.
The multimillion-dollar facility combines discovery laboratories with early-scale manufacturing infrastructure to meet growing demand for fee-for-service contracts. It brings together R&D labs and two pilot plants on a single campus, enabling an integrated route from discovery through to scale-up.
According to the company, the Noida site augments its existing Chemistry Research Innovation Centre in Greater Noida. Together, the facilities employ more than 1,300 scientists. The new site includes multiple manufacturing lines and has already onboarded several new clients.
The small-molecule hub is designed to handle quantities from hundreds of grams up to 25 kg. It includes 20,000 square feet of R&D space and 15 reactors ranging from 20 litres to 250 litres. The campus has been designed to allow future expansion, with space to potentially quadruple capacity as demand increases.
“We have grown rapidly over the past year, well above the wider market, by expanding our FFS offerings, which enable innovators to advance discovery projects with lower risk. With improving funding conditions, we anticipate even higher demand next year, and this new facility doubles our existing capabilities.”
Giuliano Perfetti, CEO of Jubilant Biosys Limited
Giuliano Perfetti added that the integrated model supports faster discovery delivery and seamless transfer to GMP facilities, supporting IND filings and later commercial phases within a CDMO and contract manufacturing framework.
